We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Decidual stromal cells for the treatment of severe COVID-19 ARDS.
- Authors
Granton, John; Novitzky-Basso, Igor N.; Binnie, Alexandra; Mattsson, Jonas; Beyea, Michael; Remberger, Mats; Moura, Clair; Lew, Judy; Yau, Cindy; Singla, Anuj; Scholz, Hanne; Fløisand, Yngvar; del Sorbo, Lorenzo; Mehta, Sanjay; Slutsky, Arthur; Laffey, John
- Abstract
A pilot study conducted in Ontario, Canada, evaluated the safety and effectiveness of placental decidual stromal cells (DSC) in treating severe acute respiratory distress syndrome (ARDS) caused by COVID-19. The study included 19 adult patients with COVID-ARDS who received DSC treatment. The results showed that DSC administration appeared safe, with one patient experiencing a transient hypoxic event related to the infusion. Survival to hospital discharge was significantly higher in the DSC group compared to a control group, and there was a trend towards increased survival to discharge from the intensive care unit. The study supports further evaluation of DSCs in larger, randomized, controlled trials to establish their safety and efficacy in treating severe ARDS.
- Subjects
ONTARIO; COVID-19 treatment; STROMAL cells; ADULT respiratory distress syndrome; PATIENT experience; INTENSIVE care units
- Publication
Intensive Care Medicine, 2023, Vol 49, Issue 12, p1552
- ISSN
0342-4642
- Publication type
Article
- DOI
10.1007/s00134-023-07262-x